Ironwood Pharmaceuticals, Inc.
Moat Score — Ironwood Pharmaceuticals, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Ironwood holds the core composition-of-matter and formulation patents behind linaclotide (LINZESS/CONSTELLA), plus settled litigation that fixes generic entry no earlier than March 2029. That said, the composition-of-matter patent expires in 2027 and the portfolio is narrow and aging, so this is a real but time-limited advantage rather than a broad IP estate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Ironwood has no manufacturing or scale cost advantage; it shares U.S. commercialization costs and profits roughly equally with AbbVie and relies on royalty deals (Astellas, AstraZeneca) abroad rather than its own low-cost infrastructure. It is a drug originator, not a low-cost operator. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | LINZESS U.S. revenue actually declined year over year (to $289.3 million in 2025) due to net price erosion and payer/channel pressure, showing limited ability to push price in a category crowded with OTC laxative alternatives and newer branded entrants like IBSRELA. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Ironwood's business — prescribing a GI constipation drug to one patient creates no additional value for other patients, physicians, or payers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a physician and patient settle on LINZESS and it works, there is some inertia to switching given established dosing and insurance prior-authorization history, but GI constipation treatment is a category where OTC and generic alternatives make switching relatively easy and common. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The U.S. IBS-C/CIC branded market supports a handful of competing therapies (LINZESS, TRULANCE, MOTEGRITY, IBSRELA, AMITIZA) alongside dominant OTC laxative volume, so it is not a naturally scale-limited niche the way a single-provider market would be; LINZESS's leadership is earned through legacy share, not structural market scarcity. |